RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06594432, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Patients with pathologically confirmed, previously untreated diffuse large B-cell lymphoma (DLBCL) who are CSF-ctDNA positive for secondary CNS lymphoma (SCNSL);

    Inclusion criterion 2

    MRI or CT of the brain showing substantial lesions in the central nervous system; patients with only meningeal lesions must have CSF cytology confirming lymphoma cells and/or imaging findings consistent with CSF examination;

    Inclusion criterion 3

  3. Received targeted therapy within 10 days before starting the study drug, or systemic chemotherapy, radiotherapy, or antibody therapy within 3 weeks before starting the study drug;

    Exclusion criterion 2

    Previous chemotherapy with unresolved toxicity (toxicity not resolved to ≤ grade 1 according to NCI-CTCAE 5.0, except for alopecia, absolute neutrophil count (ANC), and platelets);

    Exclusion criterion 6

    Patients who have not completed 4 weeks after major organ surgery;

    Exclusion criterion 11

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3;

    Inclusion criterion 4

  5. Organ function levels meeting the following requirements:Absolute neutrophil count ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥90g/L (if bone marrow is involved, platelets ≥50×10\^9/L).

    Inclusion criterion 5

    Liver function: ALT and AST ≤2.5 times the upper limit of normal, total bilirubin ≤2 times the upper limit of normal.

    Inclusion criterion 6

    Abnormal liver function (total bilirubin \>2 times the normal value, ALT or AST \>2.5 times the normal value), abnormal renal function (serum creatinine \>1.5 times the normal value);

    Exclusion criterion 3

  6. Patients with active HBV, HCV, and HIV infections;

    Exclusion criterion 9

  7. Pregnant or lactating women and patients of childbearing potential who are unwilling to use contraception;

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06594432, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years and ≤80 years, regardless of gender;
  • Patients with pathologically confirmed, previously untreated diffuse large B-cell lymphoma (DLBCL) who are CSF-ctDNA positive for secondary CNS lymphoma (SCNSL);
  • MRI or CT of the brain showing substantial lesions in the central nervous system; patients with only meningeal lesions must have CSF cytology confirming lymphoma cells and/or imaging findings consistent with CSF examination;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3;
  • Organ function levels meeting the following requirements:Absolute neutrophil count ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥90g/L (if bone marrow is involved, platelets ≥50×10\^9/L).
  • Liver function: ALT and AST ≤2.5 times the upper limit of normal, total bilirubin ≤2 times the upper limit of normal.

8.Renal function: creatinine ≤1.5 times the upper limit of normal; creatinine clearance rate ≥40 ml/min (assessed according to the Cockcroft-Gault formula or the estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal Disease [MDRD] formula).

9.Coagulation function: International Normalized Ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN.

10.Expected survival time \>3 months; 11.No radiotherapy, chemotherapy, or antibody therapy within 3 weeks before medication; no targeted therapy within 10 days before medication; 12.Female subjects of childbearing potential must agree to use effective contraception during the study and for at least 90 days after the last dose of the study drug. Male subjects must be sterilized, i.e., vasectomy, or use barrier methods, while their female partners use the aforementioned effective contraception.

13.Signed written informed consent before trial screening.

Exclusion Criteria:

  • Previous treatment with BTK inhibitors;
  • Received targeted therapy within 10 days before starting the study drug, or systemic chemotherapy, radiotherapy, or antibody therapy within 3 weeks before starting the study drug;
  • Abnormal liver function (total bilirubin \>2 times the normal value, ALT or AST \>2.5 times the normal value), abnormal renal function (serum creatinine \>1.5 times the normal value);
  • Currently have clinically significant active cardiovascular disease, such as uncontrolled arrhythmias, congestive heart failure, any grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) functional classification, or a history of myocardial infarction within 6 months before screening;
  • QTcF \>450 msecs or other significant ECG abnormalities, including second-degree type II atrioventricular (AV) block or third-degree AV block;
  • Previous chemotherapy with unresolved toxicity (toxicity not resolved to ≤ grade 1 according to NCI-CTCAE 5.0, except for alopecia, absolute neutrophil count (ANC), and platelets);
  • Patients with active bleeding;
  • Patients with active infections or persistent fever within 14 days before enrollment (excluding tumor-related fever);
  • Patients with active HBV, HCV, and HIV infections;
  • Patients with serous cavity effusion;
  • Patients who have not completed 4 weeks after major organ surgery;
  • Patients receiving strong inhibitors or strong inducers of cytochrome P450 family 3 subfamily A (CYP3A);
  • Pregnant or lactating women and patients of childbearing potential who are unwilling to use contraception;
  • Patients with mental disorders/unable to obtain informed consent;
  • Patients who abuse drugs or have long-term alcoholism that affects the evaluation of trial results;
  • Patients deemed unsuitable for participation in this study by the investigator.

Quoted from ClinicalTrials.gov, NCT06594432, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06594432, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06594432